Oscar Health Inc vs Vaxcyte Inc. Common Stock — how do they compare? Oscar Health Inc trades at $34.24 (market cap $10.43B), while Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B). The key difference: Oscar Health Inc and Vaxcyte Inc. Common Stock are close in size by market cap, and Oscar Health Inc is trading nearer its 52-week high, Vaxcyte Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Oscar Health Inc for 15 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| OSCR | PCVX | |
|---|---|---|
Market Cap | $10.43B | $10.51B |
Volume | 5,467,402 | 2,644,694 |
Sector | Health | Health |
52-Week High | $34.32 | $73.82 |
52-Week Low | $10.85 | $40.32 |
Typical Hold Time | 15 Days | 0 Days |
Enterprise Value | $6.79B | $9.14B |
Signals from Pluang's Aura AI — not financial advice
OSCR trades at $33.79, down 0.65% on the day, with strong technical momentum indicated by bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent analyst upgrades to Strong Buy reflect optimism about expanded market opportunities and margin expansion potential.
The stock presents growth potential with consensus price target of $34.75 offering modest upside. Key risks include rising medical costs threatening profitability and competitive ACA market pressures. Institutional interest remains strong with recent purchases, supporting the bullish technical outlook despite RSI indicating potential near-term overbought conditions.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →